LGC acquires antigens and antibodies company NAC
July 10, 2020 -- Life sciences company LGC has acquired the Native Antigen Company (NAC), an Oxford, U.K.-based supplier of infectious disease antigens and antibodies.
Illumina introduces sequencing software for rare genetic diseases
July 9, 2020 -- Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases.
Group calls for consistent use of genetic cancer terms
July 9, 2020 -- A consortium of cancer patient advocacy groups and other stakeholders has recommended uniform use of common terms for biomarker and germline genetic testing to better educate the public and improve access.
Reverie Labs, Roche to advance kinase drug discovery
July 8, 2020 -- Reverie Labs is partnering with Roche and Genentech to advance next-generation kinase inhibitors with the use of artificial intelligence.
Pershing Square Foundation funds SARS-CoV-2 research
July 8, 2020 -- The Pershing Square Foundation has awarded $3 million to 19 researchers investigating the novel coronavirus.
Horizon Discovery accelerates CRISPR gene editing workflows
July 7, 2020 -- Horizon Discovery Group has introduced a new stably expressing Cas9 cell line for knockout experiments and a dCas9-VPR cell line for gene activation experiments.
Tessera introduces new genome engineering strategy
July 7, 2020 -- Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing technology to cure diseases.
Parkinson's Foundation releases results of PD Generation study
July 7, 2020 -- The Parkinson's Foundation announced the preliminary results from its Parkinson's Disease (PD) Generation: Mapping the Future of PD pilot study.
Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
July 6, 2020 -- Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.
Affinity finds potent SARS-CoV-2 antibodies
July 2, 2020 -- Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against the novel coronavirus.
Conferences
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
General Discussion
Topic Replies / Views Last Update
https://academic.oup.com/ve/pages/coronavirus-evolution
by Michael
0 / 47 More than 3 days ago
by Michael
PopSci Hails Impossible Burger 2.0 as Most Important Engineering Innovation in 2019
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
Engineered Bacteria Produces BeeFree Honey
by Mahesh Gupta
0 / 12 More than 3 days ago
by Mahesh Gupta
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
by Mahesh Gupta
0 / 15 More than 3 days ago
by Mahesh Gupta
Super-precise new CRISPR tool could tackle a plethora of genetic diseases
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
To see more posts from our community or to share a post of your own, go to our community's forum page.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter